Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 175 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

 		Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma Phase1 Canada
South Korea
United States 		NCT07006727

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

 		PIK3CA-related Overgrowth Spectrum (PROS) Phase2 Australia
Austria
France 		NCT06997588

A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.

 		Charcot-Marie-Tooth Disease, Type 1A Phase1 Canada NCT07140614

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

 		Progressive Metastatic Castrate Resistant Prostate Cancer Phase1, Phase2 Australia
Malaysia
Singapore
United States
View all
 NCT07206056

Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease

 		Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease Phase4 China NCT06824103

RWE Non-Interventional Prospective Study of Ribociclib Effectiveness and Safety in Patients With HR+/HER2- Early Breast Cancer in Saudi Arabia

 		HR+/HER2- Early Breast Cancer Saudi Arabia NCT06797531

A Study to Investigate the Pharmacokinetics and Safety of Remibrutinib in Participants With Severe Renal Impairment Compared to Matched Healthy Participants.

 		Autoimmune and Chronic Inflammatory Diseases Phase1 United States NCT07032272

NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice

 		Paroxysmal Nocturnal Hemoglobinuria Russia NCT07036718

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

 		Relapsing Multiple Sclerosis Phase3 Argentina
Australia
Canada
Denmark
France
Italy
Slovakia
South Africa
Spain
Switzerland
United States
View all
 NCT06846281

Pelacarsen Roll-over Extension Program

 		Atherosclerotic Cardiovascular Disease Phase3 United States NCT06875973